The patent is related to methods and techniques that facilitate discovery of biomarkers and aid in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.
The patent describes a method of biomarker discovery using a model representative of one or more causative biophysical or biochemical relationships underlying a biological state in a biological system.
A candidate set of biological data is compared against the model to discern a candidate biomarker for the biological state.
A sample received from a patient will be assayed for the presence of the candidate biomarkers to discern a biological state of the patient.
Selventa president and CEO David Graaf said that using the technique, biomarkers may be developed to predict efficacy or toxic effects of a drug.